CYT | Cyteir Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.00 - 3.09
52 Week Range	1.6500 - 3.19
Beta	1.90
Implied Volatility	5.71%
IV Rank	0.18%
Day's Volume	1,006,884
Average Volume	167,616
Shares Outstanding	35,998,100
Market Cap	108,714,262
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-06-18

Valuation
Profitability
Growth
Health
P/E Ratio	-3.25
Forward P/E Ratio	N/A
EPS	-0.93
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	46
Country	USA
Website	CYT

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.

CYT's peers: NTRB, PTIX, CCCC, CDXC, CELC, CLGN, CLLS, CLNN, CSBR, CYCC, DYAI, ELYM, FBIOP, FENC, FHTX, GANX, GHRS, GLTO, GNFT, GNTA, HCWB, HOWL, ICCC, IMNM, IPHA, JANX, DRTS, LBPH, MNOV, MOLN, NAUT, OPT, PRLD, PRTC, RLMD, SVRA, TRVI, XLO, QNCX, LSTA, NAMS, KA

*Chart delayed

Analyzing fundamentals for CYT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see CYT Fundamentals page.

Watching at CYT technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on CYT Technicals page.